The COVID-19 pandemic in 2020 quickly changed how clinical trials are conducted. Many companies suddenly needed to switch to decentralized trial models to protect their studies and the safety of participants. Now the main question being asked is where do clinical trials go from here and what can we expect in 2021? And what does the future hold for emerging technologies, virtual trials, and patient centricity in the age of COVID?
In this webinar segment, Craig Lipset Of Clinical Innovation Partners and Debbie Profit of Otsuka discuss how technology adjustments by regulators and pharma companies to deal with trials during the pandemic will impact clinical studies in the long term. Michelle Longmire of Medable also discusses how technology companies are more permanently helping pharma transition to the use of decentralized trials.